{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:11:58Z","timestamp":1790665918048,"version":"4.1.0"},"reference-count":36,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have changed the clinical landscape of cystic fibrosis (CF) by improving clinically significant outcome measures and quality of life of people with CF (pwCF). There are now long-term data showing improved 5-year survival with the use of ivacaftor, and the field continues to evolve at a rapid pace with the continued development of highly effective CFTR modulators. While the randomized controlled trials of CFTR modulators excluded patients with severe lung disease (forced expiratory volume in 1 second &lt;40% predicted), observational data based on case reports and registry data show similar benefits in those with advanced lung disease. This has altered clinical practice particularly as it pertains to the role of lung transplantation in CF. This article describes the impact of highly effective modulator therapy (HEMT) on the natural history of CF and the influence on the timing of referral and consideration of listing for lung transplantation. CF clinicians play a pivotal role to ensure that the impetus of the CF foundation consensus guidelines to facilitate timely referral for lung transplantation is not lost among the excitement of anticipated sustained benefit from HEMT. While the widespread availability of elexacaftor\/tezacaftor\/ivacaftor over the past 2 years has been associated with a sharp drop in the number of people referred for consideration for lung transplantation and the number of people wait-listed for lung transplantation, it is difficult to accurately determine the true impact due to the confounding effect of the coronavirus disease 2019 pandemic. It is expected that lung transplantation will remain an important treatment for a smaller number of pwCF. Lung transplantation offers survival benefits in CF, and there remains an imperative to ensure timely consideration of lung transplantation in patients with advanced disease to further reduce the number of pwCF dying without consideration of lung transplant.<\/jats:p>","DOI":"10.1055\/s-0042-1758731","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T23:35:06Z","timestamp":1678404906000},"page":"260-268","source":"Crossref","is-referenced-by-count":10,"title":["Advanced Cystic Fibrosis Lung Disease and Lung Transplantation in the Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulators"],"prefix":"10.1055","volume":"44","author":[{"given":"Mark","family":"O'Carroll","sequence":"additional","affiliation":[{"name":"Respiratory Services, Auckland City Hospital, Te Toka Tumai, Te Whatu Ora \u2013 Health New Zealand, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"issue":"08","key":"ref1","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"K De Boeck","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"07","key":"ref2","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3390\/jcm10071527","article-title":"Real-world outcomes of ivacaftor treatment in people with cystic fibrosis: a systematic review","volume":"10","author":"J Duckers","year":"2021","journal-title":"J Clin Med"},{"issue":"12","key":"ref3","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1164\/rccm.201303-0429OC","article-title":"Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation","volume":"187","author":"G Thabut","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"19","key":"ref4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"P G Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.healun.2021.07.005","article-title":"Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation","volume":"40","author":"L E Leard","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.03.002","article-title":"Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines","volume":"18","author":"K J Ramos","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"18","key":"ref7","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"B W Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation","volume":"187","author":"J C Davies","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S2213-2600(14)70218-8","article-title":"Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)","volume":"2","author":"E F McKone","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1378\/chest.13-2397","article-title":"Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease","volume":"146","author":"P J Barry","year":"2014","journal-title":"Chest"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jcf.2015.01.008","article-title":"Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: safety and efficacy in an expanded access program in the United States","volume":"15","author":"J Taylor-Cousar","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.201503-0578OC","article-title":"Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data","volume":"192","author":"G S Sawicki","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"N Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting Elexacaftor-Tezacaftor-Ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"P R Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"05","key":"ref15","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jcf.2021.05.009","article-title":"Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease","volume":"20","author":"B Bermingham","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"2003079","DOI":"10.1183\/13993003.03079-2020","article-title":"Efficacy of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease","volume":"57","author":"K M O'Shea","year":"2021","journal-title":"Eur Respir J"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cell.2019.12.032","article-title":"A therapy for most with cystic fibrosis","volume":"180","author":"C E Bear","year":"2020","journal-title":"Cell"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.healun.2019.08.001","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: donor and recipient size match","volume":"38","author":"D C Chambers","year":"2019","journal-title":"J Heart Lung Transplant"},{"issue":"S 02","key":"ref19","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/ajt.16991","article-title":"OPTN\/SRTR 2020 Annual data report: Lung","volume":"22","author":"M Valapour","year":"2022","journal-title":"Am J Transplant"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: Interim results of an open-label phase 3 clinical trial","volume":"203","author":"M Griese","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"ref23","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJM199204303261804","article-title":"Prediction of mortality in patients with cystic fibrosis","volume":"326","author":"E Kerem","year":"1992","journal-title":"N Engl J Med"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jcf.2017.03.004","article-title":"A 3-year prognostic score for adults with cystic fibrosis","volume":"16","author":"L Nkam","year":"2017","journal-title":"J Cyst Fibros"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"d1008","DOI":"10.1136\/bmj.d1008","article-title":"Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007","volume":"342","author":"P M George","year":"2011","journal-title":"BMJ"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12913-017-2031-8","article-title":"Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework","volume":"17","author":"M Sekhon","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"ref27","first-page":"56","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"11","author":"K J Ramos","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"S 03","key":"ref28","first-page":"S18","article-title":"Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy","volume":"54","author":"L Saiman","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-67729-5","article-title":"Altered iron metabolism in cystic fibrosis macrophages: the impact of CFTR modulators and implications for Pseudomonas aeruginosa (PA) survival","volume":"10","author":"H F Hazlett","year":"2020","journal-title":"Sci Rep"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"21700","DOI":"10.1038\/s41598-020-78817-x","article-title":"(R)-Roscovitine and CFTR modulators enhance killing of multi-drug resistant Burkholderia cenocepacia by cystic fibrosis macrophages","volume":"10","author":"C L Shrestha","year":"2020","journal-title":"Sci Rep"},{"issue":"11","key":"ref31","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1513\/AnnalsATS.201902-122OC","article-title":"Ivacaftor is associated with reduced lung function infection by key cystic fibrosis pathogens: a cohort study using national registry data","volume":"16","author":"F J Frost","year":"2019","journal-title":"Ann Am Thorac Soc"},{"issue":"05","key":"ref32","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/cid\/ciu944","article-title":"Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor","volume":"60","author":"S L Heltshe","year":"2015","journal-title":"Clin Infect Dis"},{"key":"ref33","first-page":"346","article-title":"Long term microbiological outcomes of ivacaftor use. A single-centre retrospective study","volume":"52","author":"M McCullagh","year":"2017","journal-title":"Pediatr Pulmonol"},{"issue":"12","key":"ref34","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1002\/ppul.25637","article-title":"Twelve years of progressive Mycobacterium abscessus lung disease in CF-response to Trikafta","volume":"56","author":"M Gur","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"03","key":"ref35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/MOT.0000000000000975","article-title":"Cystic fibrosis: candidate selection and impact of the cystic fibrosis transmembrane conductance regulator therapy","volume":"27","author":"C J Lehr","year":"2022","journal-title":"Curr Opin Organ Transplant"},{"key":"ref36","first-page":"100276","article-title":"Obesity in cystic fibrosis","volume":"26","author":"K A Kutney","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"M C Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"04","key":"ref38","doi-asserted-by":"crossref","first-page":"e14007","DOI":"10.1111\/petr.14007","article-title":"To treat or not to treat: CFTR modulators after lung transplantation","volume":"25","author":"D Hayes Jr.","year":"2021","journal-title":"Pediatr Transplant"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1758731.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T17:12:09Z","timestamp":1702055529000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1758731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":36,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2023,3,9]]},"published-print":{"date-parts":[[2023,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1758731","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]}}}